Jian Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jian Song has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Bowen Gao
Department of Pharmacology School of Basic Medical Sciences Xi'an Jiaotong University Xi'an Shaanxi China
2 shared publications- Jianrong Yang
Department of Hepatobiliary, Pancreas and Spleen Surgery, Guangxi Academy of Medical Sciences, People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
2 shared publications - Junzhang Huang
Department of Hepatobiliary, Pancreas and Spleen Surgery People’s Hospital of Guangxi Zhuang Autonomous Region Nanning China
2 shared publications Lingzhang Meng
Research Laboratory, Nanning Maternity and Child Health Hospital
2 shared publications- Mingzhen Zhang
Department of Pharmacology School of Basic Medical Sciences Xi'an Jiaotong University Xi'an Shaanxi China
2 shared publications - Suosu Wei
Department of Scientific Cooperation of Guangxi Academy of Medical Sciences, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
2 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Springer Nature in Cell Death & Disease
Spatial multi-omics reveals that CXCL10 enhances the response to nICT in surgically resectable esophageal squamous cell carcinoma
Neoadjuvant immune-chemotherapy (nICT) has transformed the treatment strategy for esophageal squamous cell carcinoma (ESCC), yet the molecular mechanisms underlying treatment response remain incompletely understood. To investigate these mechanisms, we jointly analyzed matched ESCC specimens obtained before and after neoadjuvant therapy using single-cell transcriptomic profiling, spatial transcriptomics, and spatial metabolomic imaging. This multilayered, same-sample framework revealed extensive remodeling of the tumor microenvironment, including enhanced immune activation and marked changes in the spatial organization of major cellular populations. Notably, CXCL10 increased the intratumoral proportion of CD8⁺ T cells, promoted their cytotoxic activation, and enhanced T-cell–mediated tumor elimination both in vitro and in vivo. Genetic silencing or pharmacological inhibition of CXCR3 attenuated these effects and diminished the therapeutic benefit of anti-PD1 treatment, supporting a functional role for the CXCL10–CXCR3 axis in modulating immunotherapy efficacy. Spatial metabolomics further revealed pronounced remodeling of ornithine metabolism in malignant regions, characterized by suppression of the urea cycle, potential involvement of a glutamate/proline-linked ornithine pathway, and enhanced polyamine synthesis. An ornithine metabolism-related gene signature was strongly associated with poor prognosis in the TCGA-ESCC cohort, while pharmacological inhibition of ornithine decarboxylase enhanced the antitumor efficacy of anti-PD1 therapy in vivo. Together, these findings provide a spatial multi-omics atlas of ESCC following nICT and identify the CXCL10–CXCR3 axis and ornithine-centered metabolic remodeling as potentially actionable immune and metabolic features associated with treatment response.
- 15 October 2026
- Published by Springer Nature in Cell Death & Disease
Open AccessSpatial multi-omics reveals that CXCL10 enhances the response to nICT in surgically resectable esophageal squamous cell carcinoma
Neoadjuvant immune-chemotherapy (nICT) has transformed the treatment strategy for esophageal squamous cell carcinoma (ESCC), yet the molecular mechanisms underlying treatment response remain incompletely understood. To investigate these mechanisms, we jointly analyzed matched ESCC specimens obtained before and after neoadjuvant therapy using single-cell transcriptomic profiling, spatial transcriptomics, and spatial metabolomic imaging. This multilayered, same-sample framework revealed extensive remodeling of the tumor microenvironment, including enhanced immune activation and marked changes in the spatial organization of major cellular populations. Notably, CXCL10 increased the intratumoral proportion of CD8⁺ T cells, promoted their cytotoxic activation, and enhanced T-cell–mediated tumor elimination both in vitro and in vivo. Genetic silencing or pharmacological inhibition of CXCR3 attenuated these effects and diminished the therapeutic benefit of anti-PD1 treatment, supporting a functional role for the CXCL10–CXCR3 axis in modulating immunotherapy efficacy. Spatial metabolomics further revealed pronounced remodeling of ornithine metabolism in malignant regions, characterized by suppression of the urea cycle, potential involvement of a glutamate/proline-linked ornithine pathway, and enhanced polyamine synthesis. An ornithine metabolism-related gene signature was strongly associated with poor prognosis in the TCGA-ESCC cohort, while pharmacological inhibition of ornithine decarboxylase enhanced the antitumor efficacy of anti-PD1 therapy in vivo. Together, these findings provide a spatial multi-omics atlas of ESCC following nICT and identify the CXCL10–CXCR3 axis and ornithine-centered metabolic remodeling as potentially actionable immune and metabolic features associated with treatment response.
- Open Access
- 12 October 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (41) , e71833
Astragalus membranaceus ‐Derived Carbon Dots Nanozymes Ameliorate Myocardial Ischemia–Reperfusion Injury via Combined Pharmacological Action and Antioxidant Catalysis
Myocardial ischemia–reperfusion injury (MIRI) remains a major obstacle to functional recovery after myocardial infarction, primarily driven by excessive reactive oxygen species (ROS) generation, mitochondrial dysfunction, and apoptosis. In this study, we developed a straightforward hydrothermal method to synthesize Astragalus membranaceus ‐derived carbon dots (AM‐CDs), using this medicinal herb, known for its cardiovascular protective effects, as a biomass precursor. The resulting AM‐CDs exhibited broad‐spectrum ROS‐scavenging activity and pronounced biological effects against oxidative stress, inflammation, and apoptosis. In vitro experiments revealed that AM‐CDs restored mitochondrial membrane potential and reduced DNA damage, as indicated by decreased γ‐H2AX expression. Furthermore, AM‐CDs downregulated pro‐inflammatory cytokine mRNA expression in LPS‐stimulated macrophages. In a rat model of MIRI, direct intramyocardial administration of AM‐CDs resulted in a significant reduction in infarct size, improved left ventricular ejection fraction and fractional shortening in a dose‐dependent manner, and exhibited no notable systemic toxicity. Transcriptomic and protein analyses further demonstrated that AM‐CDs downregulate pro‐apoptotic proteins and modulate the PI3K‐AKT and NF‐κB‐apoptosis signaling pathways, thereby disrupting the vicious cycle of oxidative stress, inflammation, and cell death. Collectively, these findings indicate that AM‐CDs offer a promising therapeutic approach that integrates traditional medicine with nanotechnology to provide effective cardioprotection against MIRI.
- 12 October 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (41) , e71833
Open AccessAstragalus membranaceus ‐Derived Carbon Dots Nanozymes Ameliorate Myocardial Ischemia–Reperfusion Injury via Combined Pharmacological Action and Antioxidant Catalysis
Myocardial ischemia–reperfusion injury (MIRI) remains a major obstacle to functional recovery after myocardial infarction, primarily driven by excessive reactive oxygen species (ROS) generation, mitochondrial dysfunction, and apoptosis. In this study, we developed a straightforward hydrothermal method to synthesize Astragalus membranaceus ‐derived carbon dots (AM‐CDs), using this medicinal herb, known for its cardiovascular protective effects, as a biomass precursor. The resulting AM‐CDs exhibited broad‐spectrum ROS‐scavenging activity and pronounced biological effects against oxidative stress, inflammation, and apoptosis. In vitro experiments revealed that AM‐CDs restored mitochondrial membrane potential and reduced DNA damage, as indicated by decreased γ‐H2AX expression. Furthermore, AM‐CDs downregulated pro‐inflammatory cytokine mRNA expression in LPS‐stimulated macrophages. In a rat model of MIRI, direct intramyocardial administration of AM‐CDs resulted in a significant reduction in infarct size, improved left ventricular ejection fraction and fractional shortening in a dose‐dependent manner, and exhibited no notable systemic toxicity. Transcriptomic and protein analyses further demonstrated that AM‐CDs downregulate pro‐apoptotic proteins and modulate the PI3K‐AKT and NF‐κB‐apoptosis signaling pathways, thereby disrupting the vicious cycle of oxidative stress, inflammation, and cell death. Collectively, these findings indicate that AM‐CDs offer a promising therapeutic approach that integrates traditional medicine with nanotechnology to provide effective cardioprotection against MIRI.
- Open Access
Dual Antigen Display on an AP205 VLP Platform Elicits Potent and Durable Neutralization of EBV Infection in B Cells and Epithelial Cells In Vitro
Background/Objectives: Epstein–Barr virus (EBV) is a ubiquitous pathogen responsible for significant malignancies and autoimmune diseases, yet no prophylactic vaccine is available. The viral entry glycoproteins gL/gH and gB are essential for infection, but soluble forms are poorly immunogenic and fail to elicit durable neutralizing antibodies. Moreover, EBV infects both B cells and epithelial cells, demanding broad neutralization. This study aimed to develop a virus-like particle (VLP) platform that displays gL/gH and gB in a dense, repetitive array to overcome these barriers. Methods: We conjugated recombinant gL/gH and gB to Acinetobacter phage AP205 VLPs using SpyTag/SpyCatcher covalent linkage, generating monovalent and bivalent chimeric nanoparticles (co-displaying both antigens on the same particle). Mice were immunized with these VLP constructs or alum-adjuvanted soluble proteins, and antibody responses, neutralization titres against B-cell and epithelial-cell infection, as well as germinal centre responses and durability, were assessed over a four-month period. Results: AP205-conjugated nanoparticles elicited significantly higher antigen-specific IgG titres than soluble proteins. The chimeric VLP, co-displaying gL/gH and gB, induced the stronger neutralising antibodies, effectively blocking EBV entry into both B cells and epithelial cells. Mechanistically, VLP immunization drove robust and sustained germinal centre reactions, resulting in increased plasma and memory B cells, and maintained neutralising activity for at least four months. Conclusions: Precision nanoscale assembly of EBV entry glycoproteins on a synthetic VLP programs high-magnitude, broad-spectrum, and durable humoral immunity. The AP205-SpyTag platform offers a versatile and promising strategy for developing an effective prophylactic EBV vaccine.
Open AccessDual Antigen Display on an AP205 VLP Platform Elicits Potent and Durable Neutralization of EBV Infection in B Cells and Epithelial Cells In Vitro
Background/Objectives: Epstein–Barr virus (EBV) is a ubiquitous pathogen responsible for significant malignancies and autoimmune diseases, yet no prophylactic vaccine is available. The viral entry glycoproteins gL/gH and gB are essential for infection, but soluble forms are poorly immunogenic and fail to elicit durable neutralizing antibodies. Moreover, EBV infects both B cells and epithelial cells, demanding broad neutralization. This study aimed to develop a virus-like particle (VLP) platform that displays gL/gH and gB in a dense, repetitive array to overcome these barriers. Methods: We conjugated recombinant gL/gH and gB to Acinetobacter phage AP205 VLPs using SpyTag/SpyCatcher covalent linkage, generating monovalent and bivalent chimeric nanoparticles (co-displaying both antigens on the same particle). Mice were immunized with these VLP constructs or alum-adjuvanted soluble proteins, and antibody responses, neutralization titres against B-cell and epithelial-cell infection, as well as germinal centre responses and durability, were assessed over a four-month period. Results: AP205-conjugated nanoparticles elicited significantly higher antigen-specific IgG titres than soluble proteins. The chimeric VLP, co-displaying gL/gH and gB, induced the stronger neutralising antibodies, effectively blocking EBV entry into both B cells and epithelial cells. Mechanistically, VLP immunization drove robust and sustained germinal centre reactions, resulting in increased plasma and memory B cells, and maintained neutralising activity for at least four months. Conclusions: Precision nanoscale assembly of EBV entry glycoproteins on a synthetic VLP programs high-magnitude, broad-spectrum, and durable humoral immunity. The AP205-SpyTag platform offers a versatile and promising strategy for developing an effective prophylactic EBV vaccine.
- Open Access
- 12 March 2026
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 17, 1753440
Case Report: Type II tyrosinemia caused by mutations at the c.843_844 inv p.(Trp282Gly) variant locus
Objective: To identify the genetic etiology in a neonate with persistent hypertyrosinemia and characterize the functional impact of a novel TAT gene variant, c.843_844inv. Methods: A neonate suspected of having tyrosinemia type II following newborn screening by tandem mass spectrometry was recruited, along with family members. Whole-exome sequencing (WES) was performed to identify causative variants. To validate the pathogenicity of the identified novel locus, wild-type and mutant TAT expression vectors were constructed. These vectors were transfected into 293T cells to assess mRNA and protein expression levels in vitro . Structural modeling was also employed to predict the impact of the variant on protein stability. Results: The proband exhibited persistently elevated blood tyrosine levels (>600 μmol/L) on repeated screenings. Genetic analysis revealed compound heterozygous variants in the TAT gene: a known pathogenic splice-site variant, c.1125 + 1G>T (maternal), and a novel variant, c.843_844inv (p. (Trp282Gly)) (paternal). The proband’s healthy sister carried only the c.843_844inv variant. In vitro functional assays demonstrated that while TAT mRNA levels were unaffected, the p. (Trp282Gly) mutation significantly reduced TAT protein expression to approximately 20.7% of wild-type levels. Structural modeling suggested that the p. (Trp282Gly) substitution disrupts critical hydrogen bonds in the enzyme’s core region. Conclusion: A novel pathogenic variant, c.843_844inv (p. (Trp282Gly)), was identified in the TAT gene, which, in combination with c.1125 + 1G>T, causes tyrosinemia type II. Functional studies confirmed that this novel variant leads to a significant reduction in TAT protein levels. These findings expand the mutational spectrum of TAT and provide a basis for clinical diagnosis and genetic counseling.
- 12 March 2026
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 17, 1753440
Open AccessCase Report: Type II tyrosinemia caused by mutations at the c.843_844 inv p.(Trp282Gly) variant locus
Objective: To identify the genetic etiology in a neonate with persistent hypertyrosinemia and characterize the functional impact of a novel TAT gene variant, c.843_844inv. Methods: A neonate suspected of having tyrosinemia type II following newborn screening by tandem mass spectrometry was recruited, along with family members. Whole-exome sequencing (WES) was performed to identify causative variants. To validate the pathogenicity of the identified novel locus, wild-type and mutant TAT expression vectors were constructed. These vectors were transfected into 293T cells to assess mRNA and protein expression levels in vitro . Structural modeling was also employed to predict the impact of the variant on protein stability. Results: The proband exhibited persistently elevated blood tyrosine levels (>600 μmol/L) on repeated screenings. Genetic analysis revealed compound heterozygous variants in the TAT gene: a known pathogenic splice-site variant, c.1125 + 1G>T (maternal), and a novel variant, c.843_844inv (p. (Trp282Gly)) (paternal). The proband’s healthy sister carried only the c.843_844inv variant. In vitro functional assays demonstrated that while TAT mRNA levels were unaffected, the p. (Trp282Gly) mutation significantly reduced TAT protein expression to approximately 20.7% of wild-type levels. Structural modeling suggested that the p. (Trp282Gly) substitution disrupts critical hydrogen bonds in the enzyme’s core region. Conclusion: A novel pathogenic variant, c.843_844inv (p. (Trp282Gly)), was identified in the TAT gene, which, in combination with c.1125 + 1G>T, causes tyrosinemia type II. Functional studies confirmed that this novel variant leads to a significant reduction in TAT protein levels. These findings expand the mutational spectrum of TAT and provide a basis for clinical diagnosis and genetic counseling.
- Open Access
- 6 February 2026
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 17
Correction: Transcriptome profiling of intrahepatocytic Plasmodium and their host hepatocytes based on the infection phase and the zonation of the liver
- 6 February 2026
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 17
Open AccessCorrection: Transcriptome profiling of intrahepatocytic Plasmodium and their host hepatocytes based on the infection phase and the zonation of the liver
- Open Access
- 22 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Distinct immune cell dynamics associated with immune-related adverse events during combined chemoradiation and immune checkpoint inhibitor therapy
Combining chemoradiotherapy with immunotherapy increases the risk of immune-related adverse events (irAEs), but the underlying mechanisms remain poorly understood. To address this, we conducted a longitudinal single-cell multi-omics analysis of patients with locally advanced cervical cancer. Here we show that the proportions of CD4+ and CD8+ terminally differentiated effector memory or effector T cells are elevated in patients with irAEs. Chemoradiotherapy reduces B cell clonality while increasing the abundance and somatic hypermutation frequencies of IgA+ and IgG+ B cells in irAE patients. In the myeloid compartment, combined treatment expands specific monocyte subclusters associated with irAEs. Spatial transcriptomics and immunofluorescence analyses further reveal that these irAE-associated immune cells aggregate within the tumor microenvironment. Finally, we develop the predictive models for irAEs and integrate them, along with all datasets, into a user-friendly data portal. Our findings suggest that chemoradiotherapy and immunotherapy exert distinct effects on different immune cells, contributing to irAE development.
- 22 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Open AccessDistinct immune cell dynamics associated with immune-related adverse events during combined chemoradiation and immune checkpoint inhibitor therapy
Combining chemoradiotherapy with immunotherapy increases the risk of immune-related adverse events (irAEs), but the underlying mechanisms remain poorly understood. To address this, we conducted a longitudinal single-cell multi-omics analysis of patients with locally advanced cervical cancer. Here we show that the proportions of CD4+ and CD8+ terminally differentiated effector memory or effector T cells are elevated in patients with irAEs. Chemoradiotherapy reduces B cell clonality while increasing the abundance and somatic hypermutation frequencies of IgA+ and IgG+ B cells in irAE patients. In the myeloid compartment, combined treatment expands specific monocyte subclusters associated with irAEs. Spatial transcriptomics and immunofluorescence analyses further reveal that these irAE-associated immune cells aggregate within the tumor microenvironment. Finally, we develop the predictive models for irAEs and integrate them, along with all datasets, into a user-friendly data portal. Our findings suggest that chemoradiotherapy and immunotherapy exert distinct effects on different immune cells, contributing to irAE development.
- 1 September 2025
- Published by Royal Society of Chemistry (RSC) in Materials Horizons
- Vol. 12 (24) , 10880-10890
Synthesis of single-atom catalysts with reactive oxygen species-scavenging activity via the dynamic crystal structure transition of coordination polymers
Single-atom catalysts (SACs) have emerged as a research hotspot in catalysis due to their near-100% atomic utilization efficiency and unique electronic structures. However, their practical application is hindered by traditional synthesis methods, which often induce metal aggregation and fail to achieve precise control over carrier structures. Herein, a breakthrough strategy for synthesizing SACs using the dynamic structural transformation of coordination polymers (CPs) is proposed. Solvent H2O drives the transformation of the CP crystal structure from two-dimensional to one-dimensional, simultaneously triggering a drastic morphological evolution from bulk to nanosheets. Through the controlled cleavage of Cu–O coordination bonds and the synchronous reduction of partial Cu coordination centers, SACs are directly anchored on CP-derived carriers via a one-step process. This strategy ingeniously exploits the solvent-responsive structural dynamics of CPs, circumventing the destruction of carrier crystallinity caused by high-temperature treatments, and provides a novel approach for the controllable synthesis of SACs. Moreover, the synthesized SACs demonstrate exceptional ROS-scavenging capabilities, effectively alleviating oxidative stress and accelerating wound healing in diabetic mice.
- 1 September 2025
- Published by Royal Society of Chemistry (RSC) in Materials Horizons
- Vol. 12 (24) , 10880-10890
Synthesis of single-atom catalysts with reactive oxygen species-scavenging activity via the dynamic crystal structure transition of coordination polymers
Single-atom catalysts (SACs) have emerged as a research hotspot in catalysis due to their near-100% atomic utilization efficiency and unique electronic structures. However, their practical application is hindered by traditional synthesis methods, which often induce metal aggregation and fail to achieve precise control over carrier structures. Herein, a breakthrough strategy for synthesizing SACs using the dynamic structural transformation of coordination polymers (CPs) is proposed. Solvent H2O drives the transformation of the CP crystal structure from two-dimensional to one-dimensional, simultaneously triggering a drastic morphological evolution from bulk to nanosheets. Through the controlled cleavage of Cu–O coordination bonds and the synchronous reduction of partial Cu coordination centers, SACs are directly anchored on CP-derived carriers via a one-step process. This strategy ingeniously exploits the solvent-responsive structural dynamics of CPs, circumventing the destruction of carrier crystallinity caused by high-temperature treatments, and provides a novel approach for the controllable synthesis of SACs. Moreover, the synthesized SACs demonstrate exceptional ROS-scavenging capabilities, effectively alleviating oxidative stress and accelerating wound healing in diabetic mice.
- Open Access
BMSC exosomes deliver JKAP to restore Th17/Treg balance via AKT/ERK, alleviating rheumatoid arthritis
- Open Access
- 7 April 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16, 1548487
Transcriptome profiling of intrahepatocytic Plasmodium and their host hepatocytes based on the infection phase and the zonation of the liver
Intrahepatocytic development is a key stage in human Plasmodium infection, in which sporozoites replicate and transform into merozoites. Due to technological limitations, however, previous gene expression studies on malaria parasite liver infection were mostly conducted in vitro . In order to bridge these gaps, our current study compared the gene expression of in vitro -infected parasites at different time points with that of in vivo -infected parasites and revealed distinct patterns between parasite subpopulations in vitro and in vivo . A joint investigation of the Plasmodium transcriptome and their host transcriptome was carried out to confer a comprehensive analysis of gene expression in the liver stage of Plasmodium infection in vivo , which is similar to the disease setting, and therefore deepen our understanding of parasite and host transcriptional dynamics during intrahepatocytic infection.
- 7 April 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16, 1548487
Open AccessTranscriptome profiling of intrahepatocytic Plasmodium and their host hepatocytes based on the infection phase and the zonation of the liver
Intrahepatocytic development is a key stage in human Plasmodium infection, in which sporozoites replicate and transform into merozoites. Due to technological limitations, however, previous gene expression studies on malaria parasite liver infection were mostly conducted in vitro . In order to bridge these gaps, our current study compared the gene expression of in vitro -infected parasites at different time points with that of in vivo -infected parasites and revealed distinct patterns between parasite subpopulations in vitro and in vivo . A joint investigation of the Plasmodium transcriptome and their host transcriptome was carried out to confer a comprehensive analysis of gene expression in the liver stage of Plasmodium infection in vivo , which is similar to the disease setting, and therefore deepen our understanding of parasite and host transcriptional dynamics during intrahepatocytic infection.
- Open Access
- 17 February 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-15
WNT inhibitor SP5-mediated SERPING1 suppresses lung adenocarcinoma progression via TSC2/mTOR pathway
The long-term outlook for patients grappling with lung cancer (LC) remains bleak, with lung adenocarcinoma (LUAD) emerging as the most predominant histological subtype. Our Mendelian randomization (MR) investigation spotlighted that heightened levels of the circulating protein serpin peptidase inhibitor family G1 (SERPING1) substantially mitigated LC risk. The fusion of multi-omics strategies unveiled that SERPING1 exhibited diminished expression in LUAD patients compared to healthy individuals both in tissues and serum, with LUAD individuals showcasing elevated SERPING1 expression demonstrating improved prognoses. Furthermore, SERPING1 expression exhibited a robust correlation with the efficacy of immunotherapy. Through meticulous in vivo and in vitro analyses, we unraveled that SERPING1 impeded the proliferation, migration, invasion and wound healing of LUAD cells via the tuberous sclerosis 2 (TSC2)/mammalian target of rapamycin (mTOR) pathway. Mechanistically, WNT inhibitor- Specificity Protein (SP5) was delineated as facilitator of SERPING1 transcription by binding to the SERPING1 gene promoter. Intriguingly, aside from the association between SERPING1 and systolic blood pressure, glycosylated hemoglobin (HbA1c), type I diabetes, no discernible link between SERPING1 overexpression and heightened risks of other cardiometabolic conditions and diseases was evident. In summary, SERPING1 emerges as a novel tumor suppressor gene and SP5/SERPING1/TSC2 is a promising therapeutic target in the context of LUAD.
- 17 February 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-15
Open AccessWNT inhibitor SP5-mediated SERPING1 suppresses lung adenocarcinoma progression via TSC2/mTOR pathway
The long-term outlook for patients grappling with lung cancer (LC) remains bleak, with lung adenocarcinoma (LUAD) emerging as the most predominant histological subtype. Our Mendelian randomization (MR) investigation spotlighted that heightened levels of the circulating protein serpin peptidase inhibitor family G1 (SERPING1) substantially mitigated LC risk. The fusion of multi-omics strategies unveiled that SERPING1 exhibited diminished expression in LUAD patients compared to healthy individuals both in tissues and serum, with LUAD individuals showcasing elevated SERPING1 expression demonstrating improved prognoses. Furthermore, SERPING1 expression exhibited a robust correlation with the efficacy of immunotherapy. Through meticulous in vivo and in vitro analyses, we unraveled that SERPING1 impeded the proliferation, migration, invasion and wound healing of LUAD cells via the tuberous sclerosis 2 (TSC2)/mammalian target of rapamycin (mTOR) pathway. Mechanistically, WNT inhibitor- Specificity Protein (SP5) was delineated as facilitator of SERPING1 transcription by binding to the SERPING1 gene promoter. Intriguingly, aside from the association between SERPING1 and systolic blood pressure, glycosylated hemoglobin (HbA1c), type I diabetes, no discernible link between SERPING1 overexpression and heightened risks of other cardiometabolic conditions and diseases was evident. In summary, SERPING1 emerges as a novel tumor suppressor gene and SP5/SERPING1/TSC2 is a promising therapeutic target in the context of LUAD.